New study finds GLP-1 drugs lower diabetes and heart risks better than metformin
Researchers at Mayo Clinic in Scottsdale, Arizona, report that GLP-1 medications reduce blood sugar levels and cardiovascular events more effectively than the standard drug metformin for people with prediabetes.
GLP-1 drugs show superior prevention results
A new analysis indicates these treatments are more effective at treating prediabetes than the commonly prescribed medication metformin. The medications helped lower blood sugar to healthy levels in patients who have obesity and prediabetes. Users also faced a reduced chance of progressing from prediabetes to type 2 diabetes compared with those taking metformin.
Cardiovascular benefits appear significant for users
People prescribed these drugs experienced fewer heart attacks, strokes, and heart failure events than the control group. The study authors noted a lower risk of death from any cause among GLP-1 users. These findings suggest an additional option exists for treating people with prediabetes alongside standard care.
Reported by one outlet
Only one outlet has published this. Nothing here has been checked against a second report, so read it as that outlet's account and follow the link below for the original.
Reported by
1 independent outlet. Headline as published. Links open the original report.